The medical journal, Resuscitation, has published a scientific study and editorial about the Cerenion C-Trend® technology used in conjunction with the Bittium BrainStatus™ system.
The editorial inspired by the scientific study related to Cerenion’s C-Trend® technology focuses on new advances in measuring and understanding EEG after cardiac arrest. The editorial reports that present scientific knowledge is moving towards embracing EEG recording already in the first 12−24 h after cardiac arrest, instead of the old practice of recording EEG only 48–96 h after cardiac arrest. This is supported by several recent publications cited by the editorial, and by Cerenion’s own published research on the topic.
Until now, the above shift has been hindered by, for example, the fact that only 40% of all cardiac arrests occur during office hours, as noted by the editorial. The editorial also reports that even in centers where continuous EEG registration is well organized, it takes a mean of 11 h to start EEG recording, and after 12 h only about 50% of the patients are hooked onto EEG.
It is statistics such as these that Cerenion hopes to change by bringing practical EEG into routine use at the ICU. Advancing the adoption of EEG by tackling the challenges related to both carrying out and analyzing the recordings is a driving motivation behind the long-term development of the C-Trend® technology.
The scientific study, also published in Resuscitation shows that early recovery of frontal EEG slow wave activity measured with C-Trend Index predicts the outcome after cardiac arrest. When combined with Bittium’s BrainStatus EEG device, C-Trend offers a promising practical approach for early bedside evaluation of brain function in post-resuscitation care. The study was carried out in collaboration with Oulu University Hospital, University of Oulu, Helsinki University Central Hospital, University of Helsinki, and Cerenion.
About Cerenion C-Trend®
Cerenion Oy has developed the world’s ﬁrst practical method for measuring the brain function of intensive care patients. Cerenion’s patented C-Trend® technology reveals the status of the brain as one simple score – at the bed-side and without requiring any changes to the care of the patient. The solution works by combining standard EEG-measurement with advanced machine learning algorithms and artificial intelligence. The technology has the potential of improving both the quality and the cost of intensive care.